The role of IGFBP3 functional polymorphisms in the risk of gastric cancer in a high-risk Chinese population

Insulin-like growth factors (IGFs) and their receptors play a crucial role in regulating cell proliferation, differentiation, and apoptosis. Insulin-like growth factor-binding protein-3 is the most abundant insulin-like growth factor receptor in the serum and binds the majority of insulin-like growth factors. Studies reported that circulating level of insulin-like growth factor-binding protein-3 was modulated by functional genetic variants of insulin-like growth factor-binding protein-3 and, therefore, maybe associated with the risk of gastric cancer. In this case–control study of 576 gastric cancer cases and 647 cancer-free control participants in a high-risk Chinese population, we tested the hypothesis that functional polymorphisms A-202C and Gly32Ala of insulinlike growth factor-binding protein-3 are associated with risk of gastric cancer. We found that the variant 32Ala allele was associated with a significantly increased risk of gastric cancer (adjusted odds ratio=1.84, 95% confidence interval=1.45–2.33 for 32Gly/Ala and odds ratio=2.39, 95% confidence interval=1.47–3.90 for 32Ala/Ala, respectively), compared with the wild-type homozygote 32Gly/Gly. Although the A-202C variant was not significantly associated with gastric cancer risk in the single locus analysis, we found a significant locus–locus interaction between insulin-like growth factor-binding protein-3 A-202C and Gly32Ala loci on gastric cancer risk (Pint<0.001). These findings suggest that functional variants of insulin-like growth factor-binding protein-3 might be important markers for gastric cancer susceptibility and further studies are warranted to characterize the functional relevance of the locus–locus interaction of this gene.

[1]  R. Wolff,et al.  Polymorphisms in insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer. , 2006, Mutation research.

[2]  J. Chang-Claude,et al.  Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study , 2006, British Journal of Cancer.

[3]  Nicholas J Wareham,et al.  IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. , 2006, Human molecular genetics.

[4]  F. Berrino,et al.  IGF-I, IGFBP-3 and breast cancer in young women: a pooled re-analysis of three prospective studies , 2005, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[5]  J. Potter,et al.  Variation in Plasma Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3: Genetic Factors , 2005, Cancer Epidemiology Biomarkers & Prevention.

[6]  B. Henderson,et al.  Association of an Exon 1 Polymorphism in the IGFBP3 Gene with Circulating IGFBP-3 Levels and Colorectal Cancer Risk: The Multiethnic Cohort Study , 2005, Cancer Epidemiology Biomarkers & Prevention.

[7]  J. Chang-Claude,et al.  The A(-336C) insulin-like growth factor binding protein-3 promoter polymorphism is not a modulator of breast cancer risk in Caucasian women. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  N. Probst-Hensch,et al.  A new single nucleotide polymorphism in the insulin-like growth factor I regulatory region associates with colorectal cancer risk in singapore chinese. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  X. Shu,et al.  Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  S. Neuhausen,et al.  Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[12]  D. Alderson,et al.  Insulin-like growth factor binding protein-3: relationship to the development of gastric pre-malignancy and gastric adenocarcinoma (United Kingdom) , 2004, Cancer Causes & Control.

[13]  J. Witte,et al.  No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. , 2004, Cancer Epidemiology, Biomarkers and Prevention.

[14]  Ming-Rong Wang,et al.  GSTP1 polymorphisms and gastric cancer in a high-risk Chinese population , 2001, Cancer Causes & Control.

[15]  D. Hunter,et al.  Polymorphic variation at the ‐202 locus in IGFBP3: Influence on serum levels of insulin‐like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk , 2003, International journal of cancer.

[16]  T. Habuchi,et al.  Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. , 2003, Cancer research.

[17]  S. Mohan,et al.  IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. , 2002, The Journal of endocrinology.

[18]  S. London,et al.  Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. , 2002, Journal of the National Cancer Institute.

[19]  E. Wilson,et al.  Mutation of three critical amino acids of the N-terminal domain of IGF-binding protein-3 essential for high affinity IGF binding. , 2001, The Journal of clinical endocrinology and metabolism.

[20]  P. Lala,et al.  Insulin-Like Growth Factor-Binding Protein 1 Stimulates Human Trophoblast Migration by Signaling through α5β1 Integrin via Mitogen-Activated Protein Kinase Pathway1 , 2001 .

[21]  S. Narod,et al.  Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  M. Stampfer,et al.  Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. , 2001, The Journal of clinical endocrinology and metabolism.

[23]  P. Lala,et al.  Insulin-like growth factor-binding protein 1 stimulates human trophoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein Kinase pathway. , 2001, The Journal of clinical endocrinology and metabolism.

[24]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[25]  D. Clemmons,et al.  Substitutions for Hydrophobic Amino Acids in the N-terminal Domains of IGFBP-3 and -5 Markedly Reduce IGF-I Binding and Alter Their Biologic Actions* , 2000, The Journal of Biological Chemistry.

[26]  I. McCutcheon,et al.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.

[27]  M. Pollak.  Insulin-like growth factor physiology and cancer risk. , 2000, European journal of cancer.

[28]  A. Renehan,et al.  Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .

[29]  T. Eggermann,et al.  Screening for Mutations in the Promoter and the Coding Region of the IGFBP1 and IGFBP3 Genes in Silver-Russell Syndrome Patients , 1999, Human Heredity.

[30]  P. Newcomb,et al.  Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells. , 1999, Journal of molecular endocrinology.

[31]  Stampfer,et al.  Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. , 1999, Journal of the National Cancer Institute.

[32]  D. Kong,et al.  Sequence alterations of insulin-like growth factor binding protein 3 in neoplastic and normal gastrointestinal tissues. , 1998, Cancer research.

[33]  Y. Yamanaka,et al.  Insulin and IGF binding by IGFBP-3 fragments derived from proteolysis, baculovirus expression and normal human urine. , 1998, The Journal of clinical endocrinology and metabolism.

[34]  J. Kaprio,et al.  Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. , 1996, The Journal of clinical investigation.

[35]  D. Leroith,et al.  Insulin-like Growth Factors and Cancer , 1995, Annals of Internal Medicine.

[36]  D. Clemmons,et al.  Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. , 1993, Proceedings of the National Academy of Sciences of the United States of America.